Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kingworld Medicines GroupHKSE:01110 +2.47%47 PS Ratio is 0.24 as of Sep. 01, 2026, which is 45% below its 10-year median of 0.44. GuruFocus rates HKSE:01110 with a GF Score™ of 47/100 and a GF Value™ of HK$0.50 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Kingworld Medicines Group ranks better than 92.47% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kingworld Medicines Group's share price is HK$0.415.
Kingworld Medicines Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.72. Hence, Kingworld Medicines Group's PS Ratio for today is 0.24.
The historical rank and industry rank for Kingworld Medicines Group's PS Ratio or its related term are showing as below:
HKSE:01110'
s PS Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.44 Max: 1.24
Current: 0.24
During the past 13 years, Kingworld Medicines Group's highest PS Ratio was 1.24. The lowest was 0.21. And the median was 0.44.
HKSE:01110's PS Ratio is ranked better than 92.47% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 1.53
vs HKSE:01110: 0.24
Kingworld Medicines Group Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Kingworld Medicines Group was -12.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.60% per year.
During the past 13 years, Kingworld Medicines Group's highest 3-Year average Revenue per Share Growth Rate was 16.80% per year. The lowest was -10.70% per year. And the median was -0.30% per year.
Kingworld Medicines Group (HKSE:01110) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Kingworld Medicines Group PS Ratio Related Terms
Kingworld Medicines Group PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kingworld Medicines Group PS Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, Kingworld Medicines Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kingworld Medicines Group PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Kingworld Medicines Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kingworld Medicines Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Kingworld Medicines Group's Share Price of today is HK$0.415.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kingworld Medicines Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Kingworld Medicines Group (HKSE:01110) has a PS Ratio of 0.24 as of Sep. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kingworld Medicines Group and its competitors. This is 45% below median its historical median of 0.44. Over the past decade, Kingworld Medicines Group's PS Ratio has ranged from 0.21 to 1.24. According to the industry distribution chart, Kingworld Medicines Group ranks #50 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 7.5%.
Is Kingworld Medicines Group's PS Ratio too high?
Kingworld Medicines Group's current PS Ratio of 0.24 is 45% below median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 1.24. The Healthcare Providers & Services industry median PS Ratio is 1.53. Kingworld Medicines Group's value of 0.24 is 84.3% below this industry median. Based on the distribution chart, Kingworld Medicines Group ranks #50 out of 664 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Kingworld Medicines Group has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kingworld Medicines Group's PS Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Kingworld Medicines Group ranks #50 out of 664 companies for PS Ratio. This places Kingworld Medicines Group in the top 8% of its industry — outperforming the majority of peers. The industry median PS Ratio is 1.53. Kingworld Medicines Group's value of 0.24 is 84.3% below this benchmark. Historically, Kingworld Medicines Group's own PS Ratio has ranged from 0.21 to 1.24 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 1.53, Kingworld Medicines Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.53, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kingworld Medicines Group's current PS Ratio of 0.24 is 84.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kingworld Medicines Group and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kingworld Medicines Group's current PS Ratio is 0.24, which is 45% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kingworld Medicines Group stock overvalued right now?
Based on GuruFocus' analysis, Kingworld Medicines Group (HKSE:01110) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.50, compared to a current price of HK$0.42 — trading 17% below its estimated fair value. The current PS Ratio is 0.24, which is 45% below median its 10-year median of 0.44 and 84.3% below the Healthcare Providers & Services industry median of 1.53. Kingworld Medicines Group's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Kingworld Medicines Group (HKSE:01110), the current PS Ratio is 0.24 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kingworld Medicines Group (HKSE:01110) Overvalued in 2026?
Based on GuruFocus' analysis, Kingworld Medicines Group stock appears to be undervalued.
The current stock price of HK$0.42 is trading 17% below its estimated GF Value™ of HK$0.50.
GuruFocus considers Kingworld Medicines Group to be Modestly Undervalued.
Key valuation signals for HKSE:01110:
PS Ratio: 0.24 (45% below median its 10-year median of 0.44)
GF Value™: HK$0.50 vs. price of HK$0.42 (17% below fair value)
Industry Position: 84.3% below the Healthcare Providers & Services median (#50 of 664)
No single metric tells the full story. See the HKSE:01110 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kingworld Medicines Group Ltd is engaged in the Distribution of pharmaceutical and healthcare products, such as branded imported pharmaceutical and healthcare products in Hong Kong and the PRC, and Manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices carried out in the PRC. It derives the majority of its revenue from the Distribution sales of the pharmaceutical and healthcare products segment.
47GF Score
Get the complete analysis for HKSE:01110
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01110 has been successfully added to your 
